MeSH tree: D02.886.675.653
COVID-19 is rising in prevalence in many states nationally following the July 4 holiday week, but the role of the main therapy to treat it—the antiviral drug Paxlovid—is less clear.
Jul 24, 2025
0
55
As the holiday and peak respiratory seasons collide, and COVID-19 cases continue a steady, weeks-long climb, doctors want high-risk people to remember: Should COVID catch them in the coming days, one call to the doctor could ...
Dec 5, 2023
0
96
Coronaviruses are a global public health risk, with three highly infectious species, including SARS-CoV-2, emerging in the last 20 years. New research by the University of Bristol has shown how an HIV drug could stop many ...
Dec 5, 2023
0
117
The risk of long-term health problems, hospitalization and death after a COVID-19 infection diminishes among those who take the antiviral drug Paxlovid within five days after testing positive, according to an analysis of ...
Mar 24, 2023
0
73
Professor Sang Yup Lee's research team in KAIST's Department of Biochemical Engineering has developed an advanced AI-based drug interaction prediction technology that analyzed the interaction between Paxlovid ingredients ...
Mar 16, 2023
0
71
"COVID rebound," in which evidence of the illness disappears and then returns days or weeks later, is surprisingly common—whether or not patients are given the antiviral Paxlovid.
Mar 3, 2023
0
102
The antiviral pill Paxlovid not only reduces hospitalization and death after catching COVID-19: New research shows it also cuts the chances of long COVID by roughly 25%.
Nov 7, 2022
0
51
For many people with COVID, their recovery isn't linear. United States President Joe Biden is one such person—he continues to test positive for SARS-CoV-2, the virus that causes COVID, and has experienced the return of a ...
Aug 4, 2022
0
51
